Journals / Süleyman Demirel Üniversitesi Fen Bilimleri Enstitüsü Dergisi / 2020 / Cilt: 24 - Sayı: 1

Investigation of Antimicrobial and Antitubercular Activities of Some Hydrazone Derived Compounds

Bazı Hidrazon Türevi Bileşiklerin Antimikrobiyal ve Antitüberküler Etkilerinin Araştırılması

Pages
196–200
Publication Date
2020-04-20
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

However, all compounds were determined as ineffective against Escherichia coli and Escherichia coli isolate.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:A series of hydrazone derivatives were synthesized to investigate antifungal, antimicrobial and antitubercular activities.
📊
Key Findings & Data:Among the synthesized compounds B23 had the best activity against Candida albicans with 16 µg/mL MIC value and B24 had the best activity against Staphylococcus aureus isolate (MRSA) with 16 µg/mL MIC value.
💡
Conclusion & Impact:However, all compounds were determined as ineffective against Escherichia coli and Escherichia coli isolate.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Hidrazon · Antitüberküler etki · Antimikrobiyal etki

Abstract

A series of hydrazone derivatives were synthesized to investigate antifungal, antimicrobial and antitubercular activities. These activities were investigated against Escherichia coli, Escherichia coli isolate, Pseudomonas aeruginosa, Pseudomonas aeruginosa isolate (resistant to gentamicin), Staphylococcus aureus, Staphylococcus aureus isolate (MRSA), Enterococcus faecalis, Enterococcus faecalis isolate (VRE), Candida albicans, Candida krusei and Mycobacterium tuberculosis. Among the synthesized compounds B23 had the best activity against Candida albicans with 16 µg/mL MIC value and B24 had the best activity against Staphylococcus aureus isolate (MRSA) with 16 µg/mL MIC value. The most effective compound against Mycobacterium tuberculosis is found to be E9 with 32 µg/mL MIC value, a chalcone derivative. However, all compounds were determined as ineffective against Escherichia coli and Escherichia coli isolate.

Özet

Bir seri hidrazon türevi, antifungal, antimikrobiyal ve antitüberküler etkilerini araştırmak için sentezlendi. Bileşiklerin bu etkileri, Escherichia coli, Escherichia coli izolat (ESBL), Pseudomonas aeruginosa, Pseudomonas aeruginosa izolat (gentamisine dirençli), Staphylococcus aureus, Staphylococcus aureus izolat (MRSA), Enterococcus faecalis, Enterococcus faecalis izolat (VRE), Candida albicans, Candida krusei ve Mycobacterium tuberculosis karşısında araştırıldı. Sentez edilen bileşiklerden B23 Candida albicans karşısında 16 µg/mL MİK değeri ile, B24 ise Staphylococcus aureus izolatı (MRSA) karşısında 16 µg/mL MİK değeri ile en iyi etkiyi gösterdi. Mycobacterium tuberculosis karşısında en etkin bileşiğin ise 32 µg/mL MİK değeri ile bir şalkon türevi olan E9 olduğu bulundu. Bununla birlikte, tüm bileşiklerin Escherichia coli ve Escherichia coli isolat karşısında etkisiz olduğu saptandı.

🔖

Cite This Article

AKSÖZ, B. E., ONURDAĞ, F. K. K., AKSÖZ, E., ÖZGEN, S. (2020). Investigation of Antimicrobial and Antitubercular Activities of Some Hydrazone Derived Compounds. Süleyman Demirel Üniversitesi Fen Bilimleri Enstitüsü Dergisi, Cilt: 24 - Sayı: 1, 196–200. https://ajindex.com/articles/701087

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Tiberi, S., Plessis, N., Walzl, G., Vjecha, M. J., Rao, M., Ntoumi, F., Mfinanga, S., Kapata, N., Mvaba, P., McHugh, T. D., Ippolito, G., Migliori, G. B., Maeurer, M. J., Zumla, A. 2018. Tuberculosis: progress and advances in development of new drugs, treatment regimens and host-directed therapies. Lancet Infectious Disease. 18(7), e183-e198
  2. Furin, J., Cox, H., Pai, M. 2019. Tuberculosis. Lancet, 393, 1642-1656
  3. Evranos-Aksöz, B. 2014. New Drug candidates in tuberculosis treatment. Turkish Bulletin of Hygiene and Experimental Biology, 71(4), 207-220
  4. WHO. 2017. Global tuberculosis report, 2017. Geneva World Health Organization, https://reliefweb.int/report/world/global-tuberculosis-report-2017 (Accessed date: 03.01.2020
  5. Monedero, I., Caminero, J. A. 2010. Management of multidrug-resistant tuberculosis: an update. Therapeutic Advances in Respiratory Disease, 4, 117-127
  6. Yao, L., LiangLiang, C., JinYue, L., WanMei, S., Lili, S., YiFan, L., HuaiChen, L. 2019. Ambient air pollution exposures and risk of drug-resistant tuberculosis. Environment International, 124, 161-169
  7. Tong, S. Y., Davis, J. S., Eichenberger, E., Holland, T. L., Fowler, V.G. 2015. Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clinical Microbiology Reviews, 28(3), 603-661
  8. Rasigade, J. P., Vandenesch, F. 2014. Staphylococcus aureus: a pathogen with still unresolved issues. Infection Genetic Evolution, 21, 510-514
  9. Sancak, B. 2011. Staphylococcus aureus and antibiotic resistance. Bulletin of Microbiology, 45(3), 565-576
  10. Bradley, S. F. 2002. Staphylococcus aureus infections and antibiotic resistance in older adults. Clinical Infectious Diseases, 34, 211-216
  11. Xu, M., Wu, P., Shen, F., Ji, J., Rakesh, K. P. 2019. Chalcone derivatives and their antibacterial activities: current development. Bioorganic Chemistry, 91, 103-133
  12. Çetinkaya Şardan, Y. MRSA as a causative agent of nosocomial infection: prevention and control. İchastaliklaridergisi.org/managete/fu_folder/2007-03/html/2007-14-3-161-167.htm (Accessed date: 15.12.2019)
  13. Thomer, L., Schneewind, O., Missiakas, D. 2016. Pathogenesis of Staphylococcus aureus bloodstream infections. Annual Review of Pathology, 11, 343-364
  14. Lowy F. D. 1998. Staphylococcus aureus infections. The New England Journal of Medicine, 20, 339(8), 520-532
  15. Sardi, J. C. O., Scorzoni, L., Bernardi, T., Fusco-Almeida, A. M., Mendes Giannini, M. J.